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Summary
Three founder mutations in the cancer-associated genes
BRCA1 and BRCA2 occur frequently enough among
Ashkenazi Jews to warrant consideration of genetic test-
ing outside the setting of high-risk families with multiple
cases of breast or ovarian cancer. We estimated the prev-
alence of these founder mutations in BRCA1 and
BRCA2 in the general population of Ashkenazi Jews
according to age at testing, personal cancer history, and
family cancer history. We compared the results of anon-
ymous genetic testing of blood samples obtained in a
survey of 15,000 Jewish participants from the Washing-
ton, DC, area with personal and family cancer histories
obtained from questionnaires completed by the partic-
ipants. In all subgroups defined by age and cancer his-
tory, fewer mutations were found in this community
sample than in clinical series studied to date. For ex-
ample, 11 (10%) of 109 Jewish women who had been
given a diagnosis of breast cancer in their forties carried
one of the mutations. The most important predictor of
mutation status was a previous diagnosis of breast or
ovarian cancer. In men and in women never given a
diagnosis of cancer, family history of breast cancer be-
fore age 50 years was the strongest predictor. As interest
in genetic testing for BRCA1 and BRCA2 in the Jewish
community broadens, community-based estimates such
as these help guide those seeking and those offering such
testing. Even with accurate estimates of the likelihood
of carrying a mutation and the likelihood of developing
cancer if a mutation is detected, the most vexing clinical
problems remain.
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Introduction
In the brief period since BRCA1 (Miki et al. 1994) and
BRCA2 (Wooster et al. 1995) were sequenced, hundreds
of specific mutations in these two large genes have been
identified (Breast Cancer Information Core site). Two
specific mutations of BRCA1 (185delAG and 5382insC)
and one of BRCA2 (6174delT) occur relatively fre-
quently among Ashkenazi Jews (Struewing et al. 1995;
Oddoux et al. 1996) and substantially increase the like-
lihood of developing cancers of the breast, ovary, and
probably the prostate (Struewing et al. 1997). Even in
the absence of established clinical guidelines for people
who are found to carry mutations in these genes, the
level of risk and the frequency of these specificmutations
suggest the possibility of widespread testing in the Jewish
population.
Various estimates of the prevalence of mutations in
BRCA1 and BRCA2 are available from series of patients
with breast or ovarian cancers (Modan et al. 1996; Offit
et al. 1996; Beller et al. 1997; Levy-Lahad et al. 1997;
Fodor et al. 1998) and from registries of families with
multiple occurrences of these cancers (Couch et al. 1997;
Shattuck-Eidens et al. 1997; Frank et al. 1998). Before
predictive models can be extrapolated to community
screening, it is important to study larger groups drawn
from the general community.We conducted a population
survey of 5,318 Jewish men and women in the Wash-
ington, DC, area in 1996. By using the survey data, we
estimated carriers’ risks of developing cancer (Struewing
et al. 1997). In the present report, we estimate the effects
of personal and family history of cancer on the preva-
lence of any of the three BRCA1/BRCA2 mutations
common in the Jewish population.
Subjects and Methods
The study design was approved by an institutional
review board of the National Institutes of Health. In the
spring of 1996, we recruited Jewish men and women in
the Washington, DC, area by using posters, advertise-
ments, and radio announcements. Participants enrolled
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Table 1
Frequency of Three BRCA1/BRCA2 Mutations in the Washington Ashkenazi Survey









Male 10 3 18 31 1,576 2.0 1.3–2.7
Female 31 17 41 89 3,742 2.4 1.9–2.9
Cancer in subject:
Breast 9 6 11 26 288 9.0 5.7–12.3
Ovary 3 0 0 3 17 17.6 0–35.8
Prostate 0 0 2 2 48 4.2 0–9.8
Age (years, in subjects without cancer):
21–39 10 2 12 24 915 2.6 1.6–3.7
40–59 17 8 29 54 2,684 2.0 1.5–2.5
60 4 4 5 13 1,363 1.0 .4–1.5
Cancer in the family:
One breast cancer 16 8 19 43 961 4.5 3.1–5.8
Two or more breast cancers 3 4 2 9 87 10.3 3.9–16.7
Ovarian cancer 3 3 5 11 135 8.2 3.5–12.8
Prostate cancer 5 5 7 17 387 4.4 2.3–6.4
Total 41 20 59 120 5,318 2.3 1.9–2.7
at 15 sites during a 9-wk period. After giving written,
informed consent, participants completed a brief ques-
tionnaire, including information on cancers diagnosed
in their first-degree relatives, ages of relatives, and coun-
tries of origin. Information on second-degree relatives
was collected but is not included in this analysis, except
as indicated. Phlebotomists drew a sample of 100–150
ml of blood by using finger-stick procedures and trans-
ferred the blood to collection cards. PCR-based assays
were used to test DNA samples for the 185delAG and
5382insC mutations in BRCA1 and the 6174delT mu-
tation in BRCA2. A detailed description of the labora-
tory methods used is available online (Breast Cancer
Information Core site). Participants did not receive their
individual test results.
We combined carriers of any of the three mutations
because the penetrance estimates of the three were not
statistically distinguishable in these data, and combining
them led to more-stable estimates. Carrier frequencies
and approximate 95% confidence intervals (CIs) were
calculated for subgroups. Subjects with missing data,
such as age at diagnosis of the relative who developed
cancer, were excluded from analyses requiring those
data. We applied the classification and regression tree
(CART) procedure (Breiman et al. 1984) to evaluate po-
tential prediction algorithms without imposing a fixed
model of how variables interact and without assuming
that the internally generated estimates of cancer risk are
correct. Presence of a mutation was the outcome vari-
able, and personal and family history variables were in-
cluded as potential predictors. The technique recursively
partitions the data (“branches”) when partitioning on
one of the candidate variables significantly reduces the
within-set variability. We examined both additive and
multiplicative models of subsets of the data, based on
the CART models, by fitting linear binomial regression
models with the identity link (Wacholder 1986) and lo-
gistic regression models. Both linear and logistic regres-
sion models fit these data well in the groups with inter-
mediate prevalence rates. The logistic model estimates
were substantially higher than the observed frequencies
in the groups, with observed prevalence 120%. We
therefore present only the linear regression–model esti-
mates and compare them to the observed frequencies.
Results
We recruited 5,318 Jewish men and women from the
Washington, DC, area to participate in this research sur-
vey. Participants reported an average of 2.7 male and
2.7 female first-degree relatives. Family size was similar
in carriers and noncarriers. Among the 3,742 women
who volunteered for this study, 288 (8%) reported that
they been given a diagnosis of breast cancer. The median
age at diagnosis was 50 years, and the median time since
the diagnosis was 6 years. Three percent of the men who
participated reported a diagnosis of prostate cancer.
Overall, 20% of the volunteers reported that at least one
of their first-degree female relatives—that is, a mother,
daughter, or sister—had been given a diagnosis of breast
cancer. Prostate cancer in a father, brother, or son was
reported by 7% of volunteers.
In total, 2.3% (95% –2.7) of the participantsCI  1.9
carried one of the three founder mutations in BRCA1
or BRCA2 (table 1). The frequency was slightly higher
in female participants and was twice as high in partic-
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Table 2






All men and women 5,290 2.3
No breast or ovarian cancer in the subject: 4,993 1.9
No breast or ovarian cancer in family 3,935 1.2
Family history of breast or ovarian cancer: 1,058 4.2
Aged 50 years at study: 567 2.1
One breast cancer in the family 507 1.6
Multiple breast cancers in family 60 6.7
Aged !50 years at study: 491 6.6
No breast, ovarian cancer same woman 470 5.8
Breast and ovarian cancer in same woman 12 33.3
Breast or ovarian cancer in the subject: 297 9.1
Aged 40 years at diagnosis 263 6.8
Aged 60 years at diagnosis 72 1.4
Aged 40–59 years at diagnosis: 191 8.9
No breast or ovarian cancer in family 129 5.4
Breast or ovarian cancer in family 62 16.1
Aged !40 years at diagnosis 34 26.5
NOTE.—Excludes subjects with missing data. Predictors available to model
included sex; a history of either breast or ovarian cancer in the participant; a
first-degree relative with a history of either breast or ovarian cancer; a history
of both a breast cancer and an ovarian cancer occurring in the same woman;
a first-degree relative with a history of prostate cancer; a history of prostate
cancer in the subject; the decade of age at diagnosis; and the decade of age at
participation in this study.
ipants aged !40 years as in those aged 60 years. The
patterns of volunteering and the underlying likelihood
of carrying a mutation combined to determine which
subsets yielded the greatest numbers of mutation carri-
ers. Restriction to women would have identified 89
(74%) of the 120 carriers; restriction to participantswith
breast or ovarian cancer in themselves or their families
would have identified 71 (59%).
We analyzed the data as a CART, as shown in table
2. The single most important discriminator was presence
of breast or ovarian cancer in the participant. This
branching subdivided the 5,290 subjects into one branch
with personal history of one or both cancers (9.1% mu-
tation prevalence) and another branch without those
cancers (1.9% mutation prevalence). Among the breast
or ovarian cancer survivors, age at diagnosis discrimi-
nated best. Family history discriminated relatively little
if the participant herself had developed cancer, whereas,
among the other participants, family history best dis-
criminated carriers from noncarriers. Sex and several
other variables were available but did not enter the tree
because they did not produce branches with significantly
distinct prevalence rates. The lack of branching on a
particular variable—for example, the occurrence of
ovarian and breast cancer in the same woman versus no
such occurrence—can reflect either no difference in mu-
tation prevalence or such small numbers that either the
difference cannot be distinguished from chance or the
effect of the variable has already been incorporated
through another factor.
With data on cancer histories in the respondent and
the first-degree relatives only, the lowest prevalence of
a final branch on the classification tree was 1.2%, and
the highest was 33%. Although many participants ex-
pressed difficulty in recalling whether or when a second-
degree relative developed breast or ovarian cancer, others
were able to report on second-degree relatives. The ad-
dition of a variable for breast or ovarian cancers that
were reported in second-degree relatives altered only the
most detailed level of branching in the lowest prevalence
branch. That is, among the 2,870 people with no history
of breast or ovarian cancer in themselves or any first-
degree relative, the mutation prevalence in those with
an affected second-degree relative was 2.3% versus
0.8% in those without.
Acting on the importance of personal history of cancer
in classification tree results, we fitted separate linear
models for women who had not been given a diagnosis
of either breast or ovarian cancer themselves (table 3)
and those who had been given a diagnosis of either can-
cer (table 4). Among women who reported they had not
been given a diagnosis of breast or ovarian cancer, the
proportion carrying a mutation fell from 3% in those
aged !40 years to 1% in those aged 60 years. At each
age, a family history of cancer increased the likelihood
that women carried a mutation, but none of the observed
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Table 3
Frequency of Carrying Any One of Three Mutations, in Jewish Women Never Given a
Diagnosis of Breast or Ovarian Cancer







!40 years 19/690 3 3 2–4
No breast cancer in family 9/566 2 2 1–4
At least one ovarian cancer in family 0/13 0 6 3–14
Breast cancer in family 10/124 8 4 3–6
More than one relative 0/1 0 5 1–21
At least one early diagnosis 5/62 8 5 3–9
40–49 years 23/1,112 2 2 1–3
No breast cancer in family 14/888 2 2 1–3
At least one ovarian cancer in family 3/25 12 6 2–14
Breast cancer in family 9/224 4 4 2–6
More than one relative 0/7 0 5 1–21
At least one early diagnosis 6/81 7 4 2–8
50–59 years 14/811 2 2 1–3
No breast cancer in family 8/636 1 2 .6–2
At least one ovarian cancer in family 0/17 0 6 2–14
Breast cancer in family 6/175 3 3 2–5
More than one relative 2/12 17 5 1–21
At least one early diagnosis 2/56 4 4 2–9
60 years 6/806 1 1 .3–2
No breast cancer in family 4/615 1 .5 .2–1
At least one ovarian cancer in family 0/14 0 5 2–14
Breast cancer in family 2/191 1 3 1–5
More than one relative 1/28 4 4 .5–24
At least one early diagnosis 1/67 1 4 2–8
NOTE.—“Family” includes parents, siblings, and children. “Early diagnosis” refers to diagnosis
before age 50 years.
or predicted estimates exceeded 20%. For instance,
among the 224 women in their forties who reported a
positive family history of cancer, only 9 (4%) carried a
mutation. In 81 of these women, at least one of the
cancers in the family was diagnosed before age 50 years,
but only 6 (7%) of the women carried a mutation.
Among women who had been given a diagnosis of
breast or ovarian cancer, mutation prevalence fell as age
at diagnosis rose (table 4). One-quarter of the 34 women
who had been given a diagnosis of cancer before their
fortieth birthdays carried a mutation. The estimated
prevalence rose to 36% in women with more than one
relative with cancer or with an early diagnosis of cancer
in the family. Women who had been given a diagnosis
of cancer in their forties carried a mutation 10% of the
time overall, rising to 15% if another woman in the
immediate family had breast or ovarian cancer. Among
women who had been given a diagnosis of cancer in
their fifties, 7% carried a mutation; after age 60 years,
1% carried a mutation. In total, 25 of the women who
developed breast cancer themselves after age 60 years
reported breast cancer in the family, but none were mu-
tation carriers.
We compared the prevalence of mutations observed
among families with breast cancer identified in this sur-
vey to estimates from a logistic regression model based
on BRCA1 mutation analysis in families seen in breast
cancer genetics clinics (Couch et al. 1997). As the model
predicted, mutation prevalence declined with increasing
average age at diagnosis of breast cancer in the family,
but the prevalence rates were substantially lower in fam-
ilies from this community sample. For example, for a
Jewish family with no ovarian cancer and an average
age of !30 years at diagnosis, the projection from the
clinic series is 37%; for average age 30–39 years, the
projection is 48%. By comparison, we observed 26%
prevalence in the families with an average age of !40
years at diagnosis. We also compared our data to a lo-
gistic model of BRCA1 mutation prevalence derived
from 798 women in high-risk families drawn from mul-
tiple clinics (Shattuck-Eidens et al. 1997) and found
fewer than half the predicted BRCA1 mutation carriers.
One can estimate, on the basis of risks of developing
breast cancer seen in the Washington Ashkenazi Study
(13% by age 70 years in noncarriers and 56% in car-
riers), the proportion of breast cancer attributable to
mutations. Among 1,000 Jewish women, on average, 20
will carry the mutation, 11 of whom will develop breast
cancer—9 more than would if these carriers had no ex-
cess risk. On average, 127 of the 980 noncarriers will
develop breast cancer. Thus, 11 of the 138 cancers will
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Table 4
Frequency of Carrying Any One of Three Mutations, in Jewish Women Given a Diagnosis of
Breast Cancer or Ovarian Cancer







!40 years 9/34 26 26 14–44
No breast cancer in family 6/27 22 25 13–43
At least one ovarian cancer in family 0/1 0 28 10–58
Breast cancer in family 3/7 43 31 17–49
More than one relative 0/0 0 36 11–72
At least one early diagnosis 2/4 50 36 18–59
40–49 years 11/109 10 10 6–18
No breast cancer in family 6/77 8 8 4–16
At least one ovarian cancer in family 1/4 25 11 2–50
Breast cancer in family 5/32 16 15 8–25
More than one relative 2/7 29 19 3–64
At least one early diagnosis 3/9 38 19 6–44
50–59 years 6/82 7 7 3–15
No breast cancer in family 2/59 3 5 1–15
At least one ovarian cancer in family 0/3 0 8 .4–62
Breast cancer in family 4/23 17 11 5–22
More than one relative 1/2 50 16 2–66
At least one early diagnosis 2/8 25 16 5–42
60 years 1/72 1 1 .2–9
No breast cancer in family 1/47 2 1 .2–9
At least one ovarian cancer in family 0/0 0 5 .3–1
Breast cancer in family 0/25 0 8 2–22
More than one relative 0/3 0 12 .7–72
At least one early diagnosis 0/10 0 13 3–44
NOTE.—Early diagnosis refers to diagnosis before age 50 years.
test positive for mutation, 9 (6%) of them “due” to
BRCA1 or BRCA2 mutations.
Discussion
In this large survey of the Jewish community, we ob-
served fewer BRCA1/BRCA2 mutations in women who
reported breast or ovarian cancer in themselves or their
families than would be predicted from logistic regression
models based on data from cancer genetic screening clin-
ics (Couch et al. 1997; Shattuck-Eidens 1997). The ob-
served prevalence rates were substantially lower than in
Israeli ovarian cancer patients (Modan et al. 1996; Levy-
Lahad 1997). Our observation of 2% prevalence overall
generally accords with other anonymous survey results
(Struewing et al. 1995; Oddoux et al. 1996).
In any specific population, the frequency of BRCA1
or BRCA2 mutations in subgroups defined by personal
and family history of cancer reflects a combination of
parameters, beginning with the proportion of the pop-
ulation born with mutations. Differences in subsequent
events in both carriers and noncarriers alter the age-
specific carrier frequencies, including age-specific cancer
risks, any alteration of susceptibility (for example, if oo-
phorectomy and mastectomy were routine in all carri-
ers), survival after cancer diagnosis, and age-specific
risks of death from other causes. Furthermore, in par-
ticular studies, carrier frequency estimates depend on the
numbers of cancers observed, the age distribution of the
study group, data accuracy, and selection from the pop-
ulation into the study group. In this population, we es-
timate that cumulative risks of developing breast cancer
by age 50 years were 33% in carriers and 4.5% in non-
carriers; risks for ovarian cancer were 7% and 0.4%
(Struewing et al. 1997). Cumulative risks at age 70 years
were 56% for breast cancer, 13% for ovarian cancer,
and 16% for prostate cancer. The noncarriers in this
population had estimated risks of 13% for breast cancer,
1.6% for ovarian cancer, and 3.8% for prostate cancer.
Women who have been given a diagnosis of breast
cancer represent the group most likely to be offered
screening or to request it. They seek genetic information
that might bear on their risks of developing contralateral
breast cancer or ovarian cancer and the likelihood that
their relatives are at risk. Thus, it may be reassuring that
only 9% of the study participants who reported having
had breast cancer themselves tested positive. However,
some of the women who tested negative almost certainly
carried other, untested mutations in BRCA1/BRCA2 or
in unidentified cancer genes. Age at diagnosis sharply
influenced the likelihood of detecting a mutation, as ex-
pected. Indeed, women who developed breast cancer at
the oldest ages were not especially likely to carry a mu-
tation. Among women who had already developed
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breast or ovarian cancer, the additional information
gained from knowing family history was relatively small,
because the participant’s own cancer history signaled her
genotype.
Jewish women given a diagnosis of ovarian cancer also
may consider genetic testing. Ovarian cancer occurs less
frequently than breast cancer and has a worse survival
rate, so this survey included many fewer ovarian than
breast cancer survivors. These women were dispropor-
tionately likely to carry a mutation (3 [18%] of 17) but
not as likely as Israeli ovarian cancer patients have been
reported to be (Levy-Lahad et al. 1997). It is not clear
why the Israeli patients’ frequencies were higher than in
the Washington Ashkenazi Survey. Possibly, the popu-
lations differed genetically, the fairly small Israeli series
included many carriers by chance, or age or some other
factor made the Israeli cases disproportionately of ge-
netic origin.
Jewish men given a diagnosis of prostate cancer may
consider testing, even though prostate cancer risk is less
securely linked to BRCA1/BRCA2 mutations than are
either breast or ovarian cancer. In this population, the
kin-cohort analysis showed cumulative risks of prostate
cancer at age 70 years similar to those for ovarian cancer
(Struewing et al. 1997). Prostate cancer occurs at older
ages, and relatively few older men volunteered for this
study. Among the 48 prostate cancer survivors, 4% car-
ried a mutation. Similarly, 4% of the 390 participants
(mostly women) who reported prostate cancer in the
family carried a mutation.
Jewish men and women who have never been given
a diagnosis of breast or ovarian cancer constitute an-
other large group potentially interested in genetic testing,
depending on their family history. The younger the par-
ticipants are at screening, the less informative is their
own absence of cancer. In this study, 8% of unaffected
women aged !40 years carried a mutation if they re-
ported breast or ovarian cancer in the family. By con-
trast, only 1% of the unaffected women aged60 years
with positive family history were mutation carriers.
Finally, about half of the participants who volunteered
for this research study reported no personal history of
breast, ovarian, or prostate cancer and no history of
these cancers in their immediate families. Such individ-
uals are the least likely to be offered or to request genetic
testing, and these data show that such an individual has
a relatively small likelihood of being a carrier. However,
testing only people with family historywill preclude find-
ing many carriers in the general population.
Strengths of the present study include its relatively
large size and the inclusion of a broad cross-section of
the Jewish community, regardless of cancer history. The
low mutation frequencies observed in this community
survey presumably reflect the lack of selection factors
that increase the proportion of gene-related disease
among women enrolled in breast or ovarian cancer
screening clinics. Nonetheless, the survey did not con-
stitute a random sample of the entire Jewish community.
The study participants were disproportionately female,
well-educated, and affiliated with synagogues and other
Jewish organizations. As opportunities for cancer gene
testing expand, the profile of people deciding whether
or not to undergo genetic testing may increasingly re-
semble this group of volunteers. We have evaluated sur-
vival according to carrier status, using an extension of
the kin-cohort method, and found no survival advantage
or disadvantage (Lee et al. 1999). Thus, the likelihood
that a breast cancer survivor carried a mutation was not
distorted by differential survival.
Weaknesses of these data include the limitation of ge-
netic testing to the three founder mutations common in
individuals of Ashkenazi descent. Further, the findings
will not apply to other groups in which specific muta-
tions are more, or less, prevalent. This limitationmatters
especially if a site-specific mutation is found to be more,
or less, penetrant than mutations at other sites on these
large genes (Gayther et al. 1997). The lack of accounting
for other mutations may not prevent extrapolating to
other Jews of Ashkenazi descent, because few other mu-
tations have been reported in the population to date.
Other limitations of the data include errors in the re-
porting of cancers in relatives, but such errors are also
likely to occur in the more general setting of counseling
and information collection that precedes the decision
whether to offer or to accept genetic testing. Further-
more, a registry-based study of an Icelandic founder mu-
tation in BRCA2 avoided the errors of self-report and
found risks no higher than those in the current study
(Thorlacius et al. 1998), lending indirect support to the
accuracy of the cancer history data in this study. Simi-
larly, an analysis of likely carrier fractions in population-
based case-control data produced similar BRCA1-re-
lated cancer risk estimates (Whittemore et al. 1997)
One potential limitation of the present analysis is its
restriction to first-degree relationships. The analytic ap-
proach used here offers simplicity but does not exploit
all possible information in the family tree. The most
complete model needed to predict the likelihood that an
individual carries a mutation, described by Berry et al.
(1997), combines the dates of birth, death, and diag-
nosis, if any, of cancers of the breast, ovaries, or prostate
in the participant and in each member of the family,
accounting for the relation of each to the individual in
question. In principle, the model can include cancer his-
tory data from the study subject him- or herself, and
close or distant relatives. We restricted the present anal-
ysis to first-degree relatives because respondents re-
ported difficulty recalling data for more-distant relatives.
When restricted to data from first-degree relatives, the
full family history model for predicting carrier status
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from cancer risk (Berry et al 1997) is the statistical com-
plement of the kin-cohort model for predicting risk from
carrier status (Wacholder et al. 1998), the model we
developed to estimate breast, ovarian, and prostate can-
cer risks from this survey. If the cancer risk estimates
derived from the current data are correct, then appli-
cation of the full family history statistical model and the
current Ashkenazi risk estimates to additional groups of
Ashkenazi individuals ought to predict carrier status
with accuracy.
Our study does not address what likelihood of car-
rying a mutation would make testing appropriate. Re-
search on the information that individuals want and
need has been conducted in various settings, leading
some observers to recommend individualized ap-
proaches to counseling and clinical care (Lerman et al.
1996; Richards et al. 1997). The inherent uncertainty
and the possible heterogeneity in cancer risks associated
with a mutation complicate the interpretation of any
mutations detected. Equally great uncertainty attends
the interventions appropriate to reduce cancer risk if an
individual is found to carry a mutation. Thus, even if it
is possible to develop very accurate models to estimate
the likelihood that an individual of Ashkenazi descent
carries one of the easily detected founder mutations, the
most vexing clinical problems remain.
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